MicroRNA-25-5p negatively regulates TXNIP expression and relieves inflammatory responses of brain induced by lipopolysaccharide

Jiabing Wang1, Zhinan Ye2, Yuan Chen3, Xinyu Qiao2 & Yong Jin3*

Sepsis is one of the most common causes of death in patients suffering from severe infection or injury. Currently, a specific effective therapy remains to be established. In the present study, miR-25-5p, miR-105, miR-106b-5p, miR-154-3p, miR-20b-5p, miR-295-3p, miR-291-3p, miR-301b, miR-352, and miR-93-5p were predicted to target TXNIP mRNA from the databases of miRDB, Targetscan, and microT-CDS. The luciferase reporter assay confirmed that miR-25-5p negatively regulates TXNIP expression. The ELISA analyses and western blotting demonstrated that miR-25-5p downregulated the production of IL-1β, IL-6, IL-8, and TNF-α in lipopolysaccharide (LPS)-stimulated cells or rats, as well as the protein levels of TXNIP, NLRP3, and cleaved caspase-1. In addition, miR-25-5p increased the cell viability and decreased the apoptosis in LPS-stimulated CTX TNA2 cells and reduced the abnormal morphology of the brain in LPS-stimulated rats. Besides, miR-25-5p decreased the relative mean fluorescence intensity of DCF in LPS-stimulated CTX TNA2 cell, apoptosis, and protein levels of MnSOD and catalase in LPS-stimulated brains. These findings indicate that miR-25-5p downregulated LPS-induced inflammatory responses, reactive oxygen species production, and brain damage, suggesting that miR-25-5p is a candidate treatment for septic encephalopathy.

Sepsis commonly occurs in patients suffering from severe infection and injury. Sepsis syndrome is characterized by an excessive inflammatory response to infection and the inflammatory response inhibiting homeostasis1. The dysregulated inflammatory response is thought to be a result of heterogeneous microbial pathogens, specifically for gram-negative bacteria2. In severely affected patients, the dysregulated inflammatory response leads to cardiovascular, renal, and hepatic dysfunction, which are known as sepsis shock, which typically have high morbidity and mortality3,4. The excessive systemic inflammatory response can further cause inflammatory reactions in the central nervous system and brain injury, such as sepsis-associated encephalopathy or septic encephalopathy5. Unfortunately, a specific effective therapy currently remains to be established, although efforts have been made for decades. Nonetheless, previous findings on the pathological mechanism of sepsis indicate that the dysregulated inflammatory response of the host immune system is the critical pathological process involved in the development of sepsis6. A specific therapy targeting the pathological pathway of an excessively sustained inflammatory response may be an effective candidate.

MicroRNA (miRNA) is a non-coding single-stranded RNA that is composed of 18–25 nucleotides. The miRNA has been proven to be dedicated to expression regulation in the post-transcription level in organisms7. Typically, the miRNA binds to the 3’-UTR sequence of mRNA completely or partially, leading to the downregulation of the expression level of target mRNA8. Currently, many miRNAs have had their regulative activities in inflammation and immunity confirmed9,10. For example, miR-10a targets multiple key regulative components in the NF-κB signaling pathway, and the target genes include TAK 1, β-TrCP, and MAP3K711,12. miR-21 targets programmed cell death 4 and negatively regulates the TLR4 signaling pathway13,14. miR-24 can decrease the production of TNF-α and IL-6 by the suppression of HMGB1/NF-κB-associated inflammatory signaling15.

1Department of Pharmacy, Municipal Hospital Affiliated to Taizhou University, Taizhou 318000, China. 2Department of Neurology, Municipal Hospital Affiliated to Taizhou University, Taizhou 318000, China. 3Department of Neurosurgery, Municipal Hospital Affiliated to Taizhou University, Taizhou 318000, China. *email: tzmhjswk@163.com
miR-124 downregulates TLR6, MyD88, TNF-α, and TRAF6 of TLR signaling\textsuperscript{16,17}. miR-146 and miR-155 play central regulatory roles in inflammation and immunity\textsuperscript{18,19}.

The thioredoxin-interacting protein (TXNIP)/pyrin domain-containing 3 (NLRP3) pathway has been proven to be associated with the development of septic encephalopathy in recent years\textsuperscript{20}. The NLRP3 inflammasome activates the production of caspase-1 and stimulates the secretion of IL-1β and IL-18\textsuperscript{21,22}. The goal of the present study was to investigate a candidate therapy of miRNA for septic encephalopathy. We first screened miRNAs that potentially target TXNIP mRNA from miRNA databases and verify their regulative function in TXNIP expression. Secondly, we explore the function of the miRNA mimic in LPS-stimulated CTX TNA2 cells. Finally, the therapeutic function of the miRNA was further verified using in vivo experiments.

**Results**

**miR-25-5p negative regulates TXNIP expression.** We stimulated the CTX TNA2 cells with increasing lipopolysaccharide (LPS) concentration, at 1 μg/mL, 2 μg/mL, and 5 μg/mL for 12 h, and found that TXNIP RNA level was significantly increased with LPS at 2 and 5 μg/mL (Fig. 1A). We then stimulated cells LPS at 2 μg/mL in time course experiments from 0 to 24 h, and found that TXNIP RNA level was significantly at 6, 12, and 24 h (Fig. 1B). After predicting miRNAs targeting TXNIP from miRDB, Targetscan and microT-CDS, we found that 10 miRNAs, miR-105, miR-106b-5p, miR-154-3p, miR-25-5p, miR-20b-5p, miR-295-3p, miR-293-3p, miR-301b, miR-352, and miR-93-5p, were included in miRDB, Targetscan and microT-CDS, and all of them had the potential to target TXNIP (Fig. 1C). After cells were treated with 2 μg/mL LPS for 12 h, we detected the RNA level of miR-105, miR-106b-5p, miR-154-3p, miR-25-5p, miR-20b-5p, miR-293-5p, miR-293-3p, miR-301b, miR-352, and miR-93-5p, and a significant decrease in expression level was observed in miR-25-5p (t = 15.40, P < 0.0001), miR-105 (t = 14.55, P < 0.001), and miR-106b-5p (t = 6.68, P < 0.01) (Fig. 1D). We constructed plasmids encoding TXNIP 3'UTR mutants (TXNIP 3'UTR MUT) and plasmid encoding the wild-type 3'UTR of TXNIP (TXNIP 3'UTR WT) as shown in Fig. 1E. miR-25-5p mimic negative control (mimic NC) and miR-25-5p mimic were co-transfected with TXNIP 3'UTR MUT or TXNIP 3'UTR WT, and TK vector was co-transfected at the same time, and the dual-luciferase reporter assay was performed 24 h later. The result indicated that compared with cells co-transfected with mimic NC and TXNIP 3'UTR WT, luciferase activity was significantly decreased in cells co-transfected with miR-25-5p mimic and TXNIP 3'UTR WT (Fig. 1F). In contrast, luciferase activity in cells co-transfected with miR-25-5p mimic with TXNIP 3'UTR MUT did not change significantly compared to cells co-transfected with mimic NC and TXNIP 3'UTR MUTs (Fig. 1F). The mimic NC, miR-25-5p mimic, miR-25-5p inhibitor and negative control of miR-25-5p inhibitor (inhibitor NC) were transfected into CTX TNA2 cells for 24 h, the relative RNA level of miR-25-5p was significantly overexpressed by the miR-25-5p mimic (t = 83.59, P < 0.0001), but the effect of miR-25-5p inhibitor on the relative RNA level of miR-25-5p was not significant (t = 0.6478, P = 0.5524, Fig. 1G). The relative mRNA level of TXNIP was significantly decreased by the miR-25-5p mimic (t = 33.26, P < 0.0001), and contrarily was significantly increased by miR-25-5p inhibitor (t = 15.29, P < 0.0001, Fig. 1H). When the CTX TNA2 cells were stimulated with LPS at 1 μg/mL, 2 μg/mL, and 5 μg/mL for 12 h, or with 2 μg/mL LPS for 0, 6, 12, and 24 h, the miR-25-5p RNA level was downregulated by 2 μg/mL and 5 μg/mL LPS (F = 8.06, P < 0.01), and by 2 μg/mL LPS at 6, 12, and 24 h (F = 78.96, P < 0.0001) (Fig. 1I,J), which is just the reverse of TXNIP (Fig. 1A,B). These results indicated that LPS upregulated the expression of TXNIP and downregulated the level of miR-25-5p, and that miR-25-5p negatively regulated the mRNA level of TXNIP.

**miR-25-5p alleviates reactive oxygen species (ROS) response, and cell apoptosis induced by LPS.** When CTX TNA2 cells transfected with mimic NC or miR-25-5p mimic for 24 h were treated with 2 μg/mL LPS for 12 h, the expression level of miR-25-5p significantly decreased by the addition of LPS (t = 19.15, P < 0.0001), which was significantly alleviated by miR-25-5p mimic (t = 34.69, P < 0.0001) (Fig. 2A), and the expression level of TXNIP mRNA and protein in the LPS group was significantly increased by the addition of LPS (t = 25.26, P < 0.0001 for mRNA; t = 6.89, P < 0.01 for protein), which was significantly alleviated by miR-25-5p mimic (t = 2.97, P < 0.05 for mRNA; t = 4.84, P < 0.01 for protein) (Fig. 2A,B). When the CTX TNA2 cells were stimulated with LPS at 1 μg/mL, 2 μg/mL, and 5 μg/mL for 12 h, cell viability was significantly decreased by LPS at 1 μg/mL, 2 μg/mL, and 5 μg/mL (F = 154.2, P < 0.0001, Fig. 2C). CTX TNA2 cells transfected with mimic NC or miR-25-5p mimic for 24 h were treated with 2 μg/mL LPS for 12 h. The cell viability was significantly decreased by the addition of LPS (t = 18.45, P < 0.0001), which was significantly alleviated by miR-25-5p mimic (t = 34.69, P < 0.0001) (Fig. 2D). Similarly, the production of cleaved caspase-1 and NLRP3 in the LPS group was significantly stimulated by the addition of LPS (t = 25.26, P < 0.0001 for mRNA; t = 6.89, P < 0.01 for protein), which was significantly alleviated by miR-25-5p mimic (t = 2.97, P < 0.05 for mRNA; t = 4.84, P < 0.01 for protein) (Fig. 2A,B). When the CTX TNA2 cells were transfected with mimic NC or miR-25-5p mimic for 24 h were treated with 2 μg/mL LPS for 12 h, the cell viability was significantly decreased by the addition of LPS (t = 18.45, P < 0.0001), which was significantly alleviated by miR-25-5p mimic (t = 34.69, P < 0.0001) (Fig. 2D). Similarly, the production of cleaved caspase-1 and NLRP3 in the LPS group was significantly stimulated by the addition of LPS (t = 16.31, P < 0.0001 for cleaved caspase-1; t = 51.25, P < 0.0001 for NLRP3), which was significantly decreased by miR-25-5p mimic (t = 5.36, P < 0.01 for cleaved caspase-1; t = 6.49, P < 0.01 for NLRP3) (Fig. 2E). The relative mean fluorescence intensity (MFI) of DCF was significantly stimulated by the addition of LPS (t = 28.20, P < 0.0001), which was significantly reduced by the miR-25-5p mimic (t = 23.72, P < 0.0001) (Fig. 2F). Similarly, the percentage of apoptosis was significantly increased by the addition of LPS (t = 11.56, P < 0.001), which was alleviated by the miR-25-5p mimic (t = 3.17, P < 0.05) (Fig. 2G). These data revealed that increasing the level of miR-25-5p alleviated LPS-induced decrease in cell viability, production of reactive oxygen species, and increase in apoptosis.

**miR-25-5p inhibits the secretion of inflammatory factors induced by LPS.** After CTX TNA2 cells transfected with mimic NC or miR-25-5p mimic for 24 h were treated with 2 μg/mL LPS for 12 h, the supernatant of the cultured cells was collected for enzyme-linked immunosorbent assay (ELISA). A significant increase was observed in the production of IL-1β (t = 28.16, P < 0.0001), IL-6 (t = 25.26, P < 0.0001), IL-10 (t = 17.56, P < 0.0001), and TNF-α (t = 14.90, P < 0.0001) by the addition of LPS, and the stimulated production
was alleviated by the miR-25-5p mimic for IL-1β ($t = 5.94$, $P < 0.001$), IL-6 ($t = 15.81$, $P < 0.0001$), IL-10 ($t = 5.257$, $P < 0.001$), and TNF-α ($t = 7.73$, $P < 0.001$) (Fig. 3).

After rats were treated with LPS or/and AAV-miR-25-5p, the plasma was harvested for ELISA. A significant increase was observed in the concentration of IL-1β ($t = 11.43$, $P < 0.0001$), IL-6 ($t = 14.47$, $P < 0.0001$), IL-10 ($t = 8.15$, $P < 0.001$), and TNF-α ($t = 10.83$, $P < 0.0001$) after LPS injection, which was significantly alleviated by the injection of AAV-miR-25-5p for IL-1β ($t = 6.46$, $P < 0.001$), IL-6 ($t = 5.87$, $P < 0.01$), IL-10 ($t = 5.53$, $P < 0.01$), and TNF-α ($t = 5.13$, $P < 0.001$) (Fig. 4).

These findings implied that upregulation of miR-25-5p levels attenuated LPS-induced IL-1β, IL-6, IL-10, and TNF-α.
miR-25-5p alleviates brain cell damage induced by LPS. After rats were treated with LPS or/and AAV-miR-25-5p, the brain tissues were obtained for hematoxylin–eosin (HE) staining and immunohistochemical (IHC) assay. Normal morphology was observed in the brains of the control and LPS + AAV-miR-25-5p groups, and karyopyknosis was observed in the brains of the LPS and LPS + AAV-Vector group (Fig. 5A). The immunoreactivity of TXNIP and NLRP3 was detected in the brain of the LPS and LPS + AAV-Vector groups, but not in the brains of the control and LPS + AAV-miR-25-5p groups (Fig. 5B).

miR-25-5p decreases the levels of TXNIP, catalase, MnSOD, NLRP3, and cleaved caspase-1 induced by LPS. After rats were treated with LPS or/and AAV-miR-25-5p, the brain tissues were obtained for western blotting and qPCR. The miR-25-5p level in the brain of the control group was significantly higher than that in the LPS group ($t = 7.48$, $P < 0.001$), and miR-25-5p level in the brain of the LPS + AAV-miR-25-5p group was significantly greater than that in the LPS + AAV-Vector group ($t = 10.60$, $P < 0.0001$) (Fig. 6A). Similarly, significant stimulation of TXNIP ($t = 5.54$, $P < 0.01$), catalase ($t = 11.18$, $P < 0.0001$), and MnSOD ($t = 3.83$, $P < 0.05$) mRNA levels in the brain was observed in by the injection of LPS, while LPS-induced TXNIP ($t = 3.31$, $P < 0.05$), catalase ($t = 8.13$, $P < 0.001$), and MnSOD ($t = 2.92$, $P < 0.05$) mRNA levels were alleviated by the treatment of AAV-miR-25-5p (Fig. 6A). Consistently, the significant stimulation of the protein level in the brain was observed in TXNIP ($t = 6.35$, $P < 0.01$), catalase ($t = 5.14$, $P < 0.01$), cleaved caspase-1 ($t = 3.45$, $P < 0.05$), NLRP3 ($t = 4.46$, $P < 0.05$), and MnSOD ($t = 3.96$, $P < 0.05$) by the injection of LPS, which was reduced by the treatment.
of AAV-miR-25-5p for TXNIP (t = 12.99, P < 0.0001), catalase (t = 5.73, P < 0.01), cleaved caspase-1 (t = 3.60, P < 0.05), NLRP3 (t = 3.59, P < 0.05), and MnSOD (t = 3.92, P < 0.05) (Fig. 6B).

Discussion

The TXNIP expression level was positively related to the concentration and time of LPS stimulation, which is in agreement with previous findings. These findings confirmed the role of the TXNIP/NLRP3 pathway in the development of septic encephalopathy. From the miRDB, Targetscan, and microT-CDS databases, 10 miRNAs: miR-105, miR-106b-5p, miR-154-3p, miR-25-5p, miR-20b-5p, miR-295-3p, miR-291-3p, miR-301b, miR-352, and miR-93-5p, were predicted to target TXNIP mRNA. Among these miRNAs, the expression levels of miR-25-5p, miR-105, and miR-106b-5p were impacted by LPS stimulation. Especially for miR-25-5p, changes in the expression level were greatest and the expression profile was negatively related to the concentration and treatment time of LPS stimulation, in contrast to TXNIP. This evidence implied that miR-25-5p contributed to the regulation of the TXNIP/NLRP3 pathway. The regulative activity of miR-25-5p was confirmed for TXNIP expression by the luciferase reporter assay. The negative regulation of TXNIP expression by miR-25-5p indicated that the
miR-25-5p mimic might be a candidate treatment for septic encephalopathy. Nonetheless, the regulative role of miR-105 and miR-106b-5p on TXNIP expression requires further investigation to verify.

TXNIP directly interacts with NLRP3 and is essential to activate the production of the NLRP3 inflammasome. NLRP3 is a cytoplasmic signal receptor that activates caspase-1, which is involved in the maturation of IL-1β precursors. Theoretically, the downregulation of the TXNIP/NLRP3 pathway by miR-25-5p can suppress inflammatory reactions. The hypothesis was verified by in vitro and in vivo experiments. Specifically, the IL-1β protein concentration was significantly reduced in LPS-stimulated CTX TNA2 cells by miR-25-5p mimic, and the IL-1β protein concentration was significantly decreased in the plasma of LPS-stimulated rats by injection of AAV-miR-25-5p. The reduction of the inflammatory cytokine level indicated that miR-25-5p alleviated inflammatory responses. Besides, Western blot analyses showed that TXNIP, NLRP3, and cleaved caspase-1 expression levels were significantly reduced in LPS-stimulated CTX TNA2 by the miR-25-5p mimic, and TXNIP, NLRP3, and cleaved caspase-1 expression levels in the brain were significantly alleviated by treatment of the AAV-miR-25-5p group. These findings confirmed that miR-25-5p downregulated inflammatory responses by the TXNIP/NLRP3 pathway. In contrast with IL-1β, IL-6, IL-8, and TNF-α are not downstream regulation targets of the TXNIP/NLRP3 pathway. Given that miRNAs typically regulate multiple genes, the regulative target of miR-25-5p involving inflammatory responses merits further investigation.

The dysregulated inflammatory response can lead to tissue damage and organ dysfunction. In agreement with previous findings, LPS stimulated a decrease of the cell viability and increase of the percentage of apoptosis in the CTX TNA2 cells, and abnormal morphology was observed in the brains of the LPS-stimulated group. Besides, the relative MFI of DCF was significantly increased by LPS stimulation in CTX TNA2 cells. The greater relative MFI of DCF indicated increased ROS production. Consistently, the increased protein level of MnSOD and catalase in the brains of the LPS group confirmed the ROS induced by LPS stimulation. The activation of oxidative stress likely causes the damage of cells and ROS production can be stimulated by inflammatory...
Combined with the above findings, LPS activates the TXNIP/NLRP3 pathway and upregulates the inflammatory response, which leads to cell damage and tissue dysfunction.

Although we provided consistent results for the administration of miR-25-5p mimic or AAV-miR-25-5p 48 h after LPS stimulation. However, there is no substantial evidence to prove that LPS stimulation has the same effect on the central nervous system as sepsis, so this study cannot directly prove the effect of miR-25-5p on the central nervous system damage caused by sepsis, which is one of the limitations of this study. In addition, this study only investigated the role of miR-25-5p in the inflammation of CTX TNA2 cells, but failed to detect the role of miR-25-5p in the inflammation of other brain cells. Therefore, this study cannot perfectly clarify the mechanism of miR-25-5p in septicemia encephalopathy, which is also the limitation of this study.

In conclusion, in the present study, the cell viability was improved and relative MFI of DCF and percentage of apoptosis were decreased in CTX TNA2 cells by the miR-25-5p mimic treatment, and LPS-induced cell damage and abnormal morphology of the brain were alleviated by the treatment of AAV-miR-25-5p. The findings in the present study indicate that miR-25-5p plays a critical role in the inflammatory response of the brain, and miR-25-5p mimic or AAV-miR-25-5p have potential as therapeutic candidates for septic encephalopathy.

**Methods**

**Animals.** Twenty male Sprague-Dawley rats of clean-grade (200 g in weight) were purchased from Charles River (Beijing, China). The rats were housed in an animal dwelling that was kept at an ambient temperature of 23 °C and a humidity of 50%. The rats were exposed to 12 h of light per day. The animals were provided with unrestricted supplementation of food and water.

**Cell cultures.** CTX TNA2 astrocyte cell line of the rats were purchased from IMMOCELL (Xiamen, Fujian, China). The cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Detroit, MI, USA) with 100 U/ml streptomycin/penicillin, and 10% fetal bovine serum added 5% CO2 at 37 °C.
Experimental design. To understand the anti-sepsis activity of miR-25-5p in vitro, CTX TNA2 cells were allocated randomly to four groups, which were treated with blank control (physiological saline), LPS, LPS + mimic negative control (mimic NC), and LPS + miR-25-5p mimic, respectively. After transfected 200 pmol miRNA mimic with transfection reagent for 24 h, 80% confluence of cells in 6-well plates were incubated with 2 μg/ml LPS for 12 h. To understand the anti-sepsis activity of miR-25-5p in vivo, the rats were randomly allocated to four groups after 14 days of acclimatization. After anaesthetization with 1% pentobarbital sodium, twenty were randomly divided into four groups, control group which were subjected to the injection (5 mg/kg) of blank control (physiological saline), LPS group, LPS + AAV-vector group, and LPS + AAV-miR-25-5p group, with 5 rats in each group. 5 mg/kg LPS and/or 1 × 10^{12} vg/kg of AAV-miR-25-5p were injected into the rat brain of blank control (physiological saline), LPS group, LPS + AAV-vector group, and LPS + AAV-miR-25-5p group, respectively.

Ethics approval. All experiments were reported in accordance with ARRIVE guidelines\(^28\). All methods were carried out in accordance with relevant guidelines and regulations.

miRNA target prediction. miRNAs potentially binding to TXNIP mRNA were searched against the miRNA database of mirDB (http://mirdb.org/), microT-CDS (http://diana.imis.athena-innovation.gr/DianaTools/index.php?r= microT_CDS/index), and Targetscan (http://www.targetscan.org/vert_71/), using the 3'-UTR sequence of TXNIP.

Plasmid construction. The 3'-UTR sequence of TXNIP was amplified with the specific primers containing cleavage sites. After digestion with NotI and XhoI, the 3'-UTR sequence of TXNIP were recombined with the pmirGLO reporter vector (Promega, Madison, WI, USA). The QuikChange II Site-Directed Mutagenesis Kit (Agilent Technologies, CA, USA) was applied to synthesize mutant TXNIP-3'UTR plasmids. The primers are as follows. TXNIP 3'-UTR forward primer: 5'-GCTCGTAGCCGCTGAGGGCTTTAAGGGTTAAAG CCC-3', TXNIP 3'-UTR reverse primer: 5'-ATGCGTCGAGGTGACCGACACGATCCGACATGCTCAC-3'; TXNIP 3'-UTR mutant forward primer: 5'-AAACTTAAAGAATAATTTAGCATTCTTGTCCGTGCCGTCC-3', TXNIP 3'-UTR mutant reverse primer: 5'-TGCTATTATTCTTAAAGGTTTGGAGTGAGGGCC-3'.

Luciferase reporter assay. mimic NC and miR-25-5p mimic were co-transfected with TXNIP 3'UTR MUT or TXNIP 3'UTR WT using Lipofectamine 2000 reagent into CTX TNA2 cells, and TK vector was co-transfected at the same time. After lysis at 24 h post-transfection, the luciferase activities (firefly luciferase activity and Renilla luciferase activity) were determined by the Dual Luciferase Reporter Assay System (Promega, USA) and the former was normalized to the latter to estimate the expression level.

Assay of cell proliferation. The treated CTX TNA2 cells were seeded into 96-well plates. The density per well was approximately 10^4 cells. After the incubation with a cell counting kit 8 solution, the viability of the CTX TNA2 cells was determined by an absorbance reader (SpectraMax, San Francisco, CA, USA) at an absorbance of 450 nm.

Assay of ROS. To detect the ROS, the treated CTX TNA2 cells were stained with 10 μmol/L DCFH-DA (catalog number: S0033S, Beyotime). The cells were then diluted with RPMI 1640 medium. The ROS intensity was measured by a flow cytometer (ACEA, San Diego, CA, USA).

Assay of cell apoptosis. The treated CTX TNA2 cells were incubated with annexin V-fluorescein isothiocyanate and propidium iodide reagents (Vazyme, Nanjing, China) following the manufacturer's instruction. The apoptotic cells were determined by a flow cytometer (ACEA, San Diego, CA, USA) and the proportion of apoptotic cells was calculated.

Sampling of blood and brain. After 48 h post-injection, blood was sampled from the tail vein of the rats. The blood sample was centrifuged for 10 min at 3000 x g to obtain plasma. The rats were then euthanized with pentobarbital and the brain was immediately sampled after dissection. After collection, the blood and brain samples were immediately frozen in liquid nitrogen. The frozen samples were transferred to a −80 °C freezer for storage until further analyses.

HE staining. For histological observation, the brain sample was fixed with 10% formalin. The washed sample was embedded in paraffin, followed by sectioning (5 μm). The sections were stained by HE to obtain HE slides. The slides were observed by an Olympus light microscope (BX51, Olympus corporation).

IHC assay. For immunohistochemical observation, the sections of the brain sample were deparaffinized, rehydrated, and treated with 3% H₂O₂ followed by the addition of citrate buffer. The blocked sections were incubated with TXNIP antibody (catalog number: 18243-1-AP, Proteintech, Wuhan, China), or NLRP3 antibody (catalog number: 19771-1-AP, Proteintech), followed by incubation with the HRP-conjugated goat anti-rabbit IgG (catalog number: SA00001-2, Proteintech). The sections were subsequently treated with a 3,3-diaminobenzidine substrate system. The slides were observed using an Olympus light microscope (BX51, Olympus corporation).
An enzyme-linked immunosorbent assay (ELISA). Rat IL-1β/IL-1F2 ELISA Kit (catalog number: RLB00, China Bio-Techne China Co., Ltd.), Rat IL-6 ELISA Kit (catalog number: R6000B, China Bio-Techne China Co., Ltd.), Rat IL-10 ELISA Kit (catalog number: R1000, China Bio-Techne China Co., Ltd.), Rat TNF-α ELISA Kit (catalog number: RTA00, China Bio-Techne China Co., Ltd., Shanghai, China) were applied to determine the protein concentration of IL-1β, IL-6, IL-10, and TNF-α, and the protein concentration was determined by a microplate reader (BMG Labtech, VIC, Australia) at an absorbance of 450 nm, following the manufacturer’s instructions. The variations of intra- and inter-assay were both <10% in the present study.

Western blotting. The proteins of the brain samples were isolated with RIPA lysis buffer, which is composed of protease, phosphatase inhibitors, and PMSF (Beyotime, Shanghai, China). After separation by SDS-PAGE gel, the proteins were transferred to polyvinylidene difluoride membranes (Bio-Rad, Hercules, CA, USA), which was blocked with 5% non-fat milk. The membrane was incubated with primary antibodies (anti-TXNIP, anti-catalase, anti-MnSOD, anti-caspase-8, and anti-NLRP3) and HRP-conjugated secondary antibodies. The HRP chemiluminescence kit (Immun-StarTM, Bio-Rad) was used to visualize protein bands on the ImageQuant LAS 4000 system (GE Healthcare, Hino, Japan). Primary antibodies were TXNIP antibody (catalog number: 18243-1-AP, Proteintech, Wuhan, China), catalase antibody (catalog number: 21260-1-AP, Proteintech), MnSOD antibody (catalog number: ab15353, Abcam, Shanghai, China), caspase-1 antibody (catalog number: #4199, Cell Signaling Technology, Shanghai, China), NLRP3 antibody (catalog number: ab214185, abcam), GAPDH (catalog number: 21260-1-AP, Proteintech). Secondary antibodies were HRP-conjugated Goat Anti-IgG (catalog number: 4001A, LifeTech, Shanghai, China), and HRP-conjugated Goat Anti-Rabbit IgG (catalog number: 4004A, LifeTech, Shanghai, China).

RNA extraction and first-strand cDNA synthesis. The total RNA was extracted using TRIzol reagents (TaKaRa) for mRNAs and the miRNana TM miRNA isolation kit (Ambion, Austin) for miRNAs, following manufacturer’s instructions. The quality of extraction was assessed by agarose gel electrophoresis and UV spectrophotometry. The total RNA was treated with DNase I (TaKaRa). The mRNAs and miRNAs were reverse-transcribed using commercial kits (TaKaRa), according to manufacturer’s instructions. The variations of intra- and inter-assay were both <10% in the present study.

Real-time quantitative PCR. Real-time quantitative PCR (qPCR) was applied to determine the expression level of mRNA and miRNA in a QuantiStudio 3 Real-time PCR System (Thermo Scientific, MA, USA) using TB Green Premix Ex TaqTM II (TaKaRa, Dalian, China). The PCR reaction was programmed as per the following parameters: preheating at 95 °C for 60 s, 40 repeated cycles of heating at 95 °C for 30 s, cooling at 58 °C for 35 s, extension at 72 °C for 60 s, and a final extension at 72 °C for 10 min. The relative expression level was calculated using the 2−ΔΔCT algorithm (Livak and Schmittgen 2001), in which glyceraldehyde-3-phosphate dehydrogenase was used as the internal control. 18 s RNA was selected as an internal control for qPCR of TXNIP, Catalase, and MnSOD. U6 was chosen as an internal control for qPCR of miRNAs. Information on the PCR primers is provided in the “Supplementary material”.

Statistical analysis. All statistical analyses were conducted on Graph Pad Prism 3.0 software (San Diego, California, USA). The independent t-test was applied to the comparison between groups, and the normality of data was verified by the Shapiro–Wilks test. One-way analysis of variance (ANOVA), followed by Tukey’s test was used for post hoc analysis.
used to identify the significant differences among multiple groups. A significant difference was considered when $P<0.05$. All cell experiments were performed independently for more than three times.

**Data availability**

The data of miRNAs are available from miRDB (http://mirdb.org/), microT-CDS (https://diana.lab.e-ce.uth.gr/html/dianauniverse/index.php?r=miRDB), and Targetscan (https://www.targetscan.org/vert_72/). Other materials used during the present study are available from the corresponding author on reasonable request.

Received: 8 April 2022; Accepted: 23 September 2022
Published online: 26 October 2022

**References**

1. Bone, R. C. et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. *Chest* **101**(6), 1644–1655 (1992).
2. Shapiro, L. & Gelfand, J. A. Cytokines and sepsis: Pathophysiology and therapy. *New Horizons (Baltimore, Md)*. 1(1), 13–22 (1993).
3. Cossart, Y. E. The rise and fall of infectious diseases: Australian perspectives, 1914–2014. *Med. J. Aust.* **201**(1 Suppl), S11–S14 (2014).
4. Singer, M. et al. The third international consensus definitions for sepsis and septic shock (sepsis-3). *JAMA* **315**(8), 801–810 (2016).
5. Barbosa-Silva, M. C. et al. Infectious disease-associated encephalopathies. *Crit. Care (Lond. Engl.)*. 25(1), 236 (2021).
6. van der Poll, T., van de Veerdonk, F. L., Scicluna, B. P. & Netea, M. G. The immunopathology of sepsis and potential therapeutic targets. *Nat. Rev. Immunol.* **17**(7), 407–420 (2017).
7. Litz, J. et al. Regulation of pri-miRNA processing by a long noncoding RNA transcribed from an ultraconserved region. *Mol. Cell* **55**(1), 138–147 (2014).
8. Tang, G. siRNA and miRNA: An insight into RISCs. *Trends Biochem. Sci.* **30**(2), 106–114 (2005).
9. Chandan, K., Gupta, M. & Sarwat, M. Role of host and pathogen-derived microRNAs in immune regulation during infectious and inflammatory diseases. *Front. Immunol.* **10**, 3081 (2019).
10. Zhou, H., Ni, W. J., Meng, X. M. & Tang, L. Q. MicroRNAs as regulators of immune and inflammatory responses: Potential therapeutic targets in diabetic nephropathy. *Front. Cell Dev. Biol.* **8**, 618536 (2020).
11. Mu, N. et al. A novel NF-κB/YY1/microRNA-10a regulatory circuit in fibroblast-like synoviocytes regulates inflammation in rheumatoid arthritis. *Sci. Rep.* **6**, 20059 (2016).
12. Zheng, G. et al. miR-10a in peripheral blood mononuclear cells is a biomarker for sepsis and has anti-inflammatory function. *Mediators Inflamm.* **2020**, 4370983 (2020).
13. Chakraborty, A. et al. Programmed cell death in aortic aneurysm and dissection: A potential therapeutic target. *J. Mol. Cell. Cardiol.* **163**, 67–80 (2022).
14. Sheedy, F. J. et al. Negative regulation of TLR4 via targeting of the proinflammatory tumor suppressor PDCD4 by the microRNA miR-21. *Nat. Immunol.* **11**(2), 141–147 (2010).
15. Yang, J. et al. MicroRNA-24 inhibits high glucose-induced vascular smooth muscle cell proliferation and migration by targeting HMGB1. *Gene* **586**(2), 268–273 (2016).
16. Ma, C. et al. microRNA-124 negatively regulates TLR signaling in alveolar macrophages in response to mycobacterial infection. *Mol. Immunol.* **62**(1), 150–158 (2014).
17. Han, D., Dong, X., Zheng, D. & Nao, J. MiR-124 and the underlying therapeutic promise of neurodegenerative disorders. *Front. Pharmacol.* **10**, 1555 (2019).
18. Foster, P. S. et al. The emerging role of microRNAs in regulating immune and inflammatory responses in the lung. *Immunol. Rev.* **253**(1), 198–215 (2013).
19. Sun, X. H. et al. miR-155 mediates inflammatory injury of hippocampal neuronal cells via the activation of microglia. *Mol. Med.* **19**(4), 2627–2635 (2019).
20. Yang, C., Xia, W., Liu, X., Lin, J. & Wu, A. Role of TXNIP/NLRP3 in sepsis-induced myocardial dysfunction. *Int. J. Mol. Med.* **44**(2), 417–426 (2019).
21. Kelley, N., Jelfema, D., Duan, Y., He, Y. (2019) The NLRP3 inflammasome: An overview of mechanisms of activation and regulation. *Int. J. Mol. Sci.* **20**(13).
22. Linson, K. V., Deng, M. & Ting, J. P. The NLRP3 inflammasome: Molecular activation and regulation to therapeutics. *Nat. Rev. Immunol.* **19**(8), 477–489 (2019).
23. Nishiyama, A. et al. Identification of thioredoxin-binding protein-2/vitamin D(3) up-regulated protein 1 as a negative regulator of thioredoxin function and expression. *J. Biol. Chem.* **274**(31), 21645–21650 (1999).
24. Shen, H. H. et al. NLRP3: A promising therapeutic target for autoimmune diseases. *Autoimmun. Rev.* **17**(7), 694–702 (2018).
25. Iqroh, S. et al. MicroRNAs are potential prognostic and therapeutic targets in diabetic osteoarthritis. *J. Bone Miner. Metab.* **33**(1), 1–8 (2015).
26. Anthonymuthu, T. S., Kim-Campbell, N. & Bayır, H. Oxidative lipidomics: Applications in critical care. *Curr. Opin. Crit. Care* **23**(4), 251–256 (2017).
27. Back, S. et al. Neuron-specific genome modification in the adult rat brain using CRISPR-Cas9 transgenic rats. *Neuron* **102**(1), 105–19.e8 (2019).
28. Kilkenny, C., Browne, W. J., Cuthill, I. C., Emerson, M. & Altman, D. G. Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. *PLoS Biol.* **8**(6), e1000412 (2010).

**Acknowledgements**

The present study was financially supported by the Medical Health Science and Technology Project of Zhejiang Provincial Health Commission (No. 2021KY1216). We appreciate the assistance of our colleagues in sampling and processing.

**Author contributions**

J.W. and Y.C. performed the research and wrote the manuscript. Z.Y. and X.Q. analyzed the data. Y.J. designed the research. All authors read and approved the final manuscript.

**Competing interests**

The authors declare no competing interests.
Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-022-21169-5.

Correspondence and requests for materials should be addressed to Y.J.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022